Larvol Delta - Study-to-evaLuate-the-effIcacy-and-Safety-of-abeLacimab-in-Highrisk-Patients-With-Atrial-Fibrillation-Who-Have-Been-Deemed-Unsuitable-for-Oral-antiCoagulation-LILACTIMI-76

abelacimab (MAA868) - Anthos Therapeutics

http://clinicaltrials.gov/ct2/show/NCT05712200

Jul 14, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next